PNC-27

antineoplastic; a peptide that contains an HDM-2-binding domain from p53 attached to a membrane-penetrating peptide on its carboxyl terminal end, is cytotoxic to cancer, but not normal cells; amino acid sequence in first source

Networked: 14 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pincus, Matthew R: 10 articles (04/2022 - 02/2004)
2.	Bowne, Wilbur B: 8 articles (04/2022 - 02/2010)
3.	Michl, Josef: 8 articles (04/2022 - 02/2004)
4.	Sarafraz-Yazdi, Ehsan: 8 articles (04/2022 - 02/2010)
5.	Thadi, Anusha: 4 articles (04/2022 - 09/2020)
6.	Adler, Victor: 4 articles (01/2014 - 02/2010)
7.	Morano, William F: 3 articles (04/2022 - 09/2020)
8.	Campbell, Paul M: 3 articles (01/2021 - 09/2020)
9.	Goldstein, Eve: 3 articles (01/2021 - 09/2020)
10.	Khalili, Marian: 3 articles (01/2021 - 09/2020)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2015 - "These findings show, for the first time, the efficacy of PNC-27 on freshly isolated, primary human cancer cells. " 01/01/2021 - "Bioluminescence imaging measured PNC-27 effects on in vivo tumor growth. " 02/02/2010 - "We conclude that PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively." 01/01/2015 - "Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer." 01/01/2021 - "In vivo, PNC-27 caused necrosis of tumor nodules but not of normal tissue. "
2.	Ovarian Epithelial Carcinoma 01/01/2015 - "The purpose of this study was to evaluate the efficacy of PNC-27 against human primary epithelial ovarian cancer. " 01/01/2015 - "Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer." 01/01/2015 - "PNC-27 inhibits in a dose-dependent manner the growth of and is cytotoxic to human primary cancer cells that had been freshly isolated from two ovarian epithelial cancers. " 09/01/2020 - "We therefore conclude that the association of PNC-27 with preferentially expressed membrane HDM-2 isoforms results in the proposed model for the formation of transmembrane pores and epithelial ovarian cancer tumor cell necrosis, as previously described in a number of solid tissue and hematologic malignancies."
3.	Ovarian Neoplasms (Ovarian Cancer) 09/01/2020 - "Our results suggest that HDM-2 is highly expressed in the membranes of these ovarian cancer cell lines and colocalizes with PNC-27. " 01/01/2015 - "Our results also show that PNC-27 is cytotoxic to cells from long-established and chemotherapy-resistant human ovarian cancer cell lines. " 09/01/2020 - "We aimed to extend these studies further by investigating expression of membrane HDM-2 protein in ovarian cancer as it relates to susceptibility to PNC-27. " 05/01/2017 - "The goal of this study is to assess ovarian cancer cells' sensitivity to PNC-27 after surviving exposure to paclitaxel and to investigate the potential for synergy between PNC-27 and paclitaxel in the treatment of ovarian cancer. " 05/01/2017 - "The combined treatment with weekly paclitaxel and PNC-27 was tested in an intraperitoneal mouse model of ovarian cancer (ID8). "
4.	Necrosis 09/01/2020 - "PNC-27 can bind to membrane HDM-2 to induce cell necrosis and LDH release within 4 h. " 01/01/2021 - "In vivo, PNC-27 caused necrosis of tumor nodules but not of normal tissue. " 09/01/2020 - "Notably, PNC-27 colocalized with HDM-2 in the membranes of both cancer cell lines that resulted in rapid cellular necrosis. " 09/01/2020 - "Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells." 01/01/2014 - "Since PNC-27 induces necrosis of K-562 leukemia cells and co-localizes with HDM-2 in the tumor cell membrane as an early event, we conclude that the association of PNC-27 with HDM-2 in the cancer cell membrane results in trans-membrane pore formation which results in cancer cell death, as previously discovered in a number of different solid tissue tumor cells. "
5.	Leukemia 09/01/2020 - "PNC-27 targeting membrane HDM-2 demonstrated significant anti-leukemia activity in a variety of leukemic cell lines." 01/01/2014 - "Since K562 cells lack p53 expression, these effects of PNC-27 on this leukemia cell line occur by a p53-independent pathway." 09/01/2020 - "Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells." 01/01/2014 - "Since PNC-27 induces necrosis of K-562 leukemia cells and co-localizes with HDM-2 in the tumor cell membrane as an early event, we conclude that the association of PNC-27 with HDM-2 in the cancer cell membrane results in trans-membrane pore formation which results in cancer cell death, as previously discovered in a number of different solid tissue tumor cells. " 01/01/2014 - "The anti-cancer activity and mechanism of PNC-27, which carries a p53 aa12-26-leader sequence connected on its carboxyl terminal end to a trans-membrane-penetrating sequence or membrane residency peptide (MRP), was studied against p53-null K562 leukemia cells. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Proteins (Proteins, Gene)
3.	Paclitaxel (Taxol)
4.	PNC-28
5.	Cell-Penetrating Peptides
6.	Caspase 3 (Caspase-3)
7.	Caspases
8.	Sirolimus (Rapamycin)
9.	Protein Isoforms (Isoforms)
10.	Annexin A5

Related Therapies and Procedures

1.	Ketogenic Diet
2.	Drug Therapy (Chemotherapy)